期刊
EXPERIMENTAL CELL RESEARCH
卷 345, 期 2, 页码 158-167出版社
ELSEVIER INC
DOI: 10.1016/j.yexcr.2015.09.012
关键词
ANGPTL8/betatrophin; Akt; GSK3 beta; FoxO1; Insulin resistance; HepG2 cells
资金
- Major Science and Technology Projects of China [2013ZX10001-004-002-005]
- National Natural Science Foundation of Hubei province [2012FFA037]
- National Foundation of College Students' Innovative Entrepreneurial Training Program [201410929005]
- Hubei Province Health and Family Planning Scientific Research Project [WJ2015MB223]
Angiopoietin-like protein 8 (ANGPTL8)/betatrophin, a newly identified protein, is primarily expressed in the liver and regulates the glucose metabolic transition during fasting and re-feeding in mice with or without insulin resistance. These findings strongly suggest that ANGPTL8/betatrophin could be a novel glucose-lowering candidate medicine for type 2 diabetes. However, the molecular mechanisms by which ANGPTL8/betatrophin regulates glucose metabolism are poorly understood in human. Two sub-clones of HepG2 cells, ANGPTL8/betatrophin knockouts and ANGPTL8/betatrophin over-expressors, were established using TALENs (transcription activator-like effector nucleases) and through stable transfection, respectively. Over-expression of ANGPTL8/betatrophin enhanced the insulin-stimulated activation of the Akt-GSK3 beta or Akt-FoxO1 pathway, no matter whether the cells were present with insulin resistance or not. In contrast, knockout of ANGPTL8/betatrophin did not affect the Akt-GSK3 beta or Akt-FoxO1 pathway unless the HepG2 cells were preset with insulin resistance. Our results suggest that ANGPTL8/betatrophin might play an important role in glucose metabolism in the context of insulin resistance. (C) 2016 Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据